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scenarios from removing a PA on lubiprostone when cost per PA
>$15.34 or PA approval rate >74.83%, or expected increase in
prescriptions from lifting PA <19.99%. CONCLUSION: PA
program for lubiprostone offers no ﬁnancial savings to a health
plan based on current approval rates and annual utilization for
patients suffering from CC in the base case as well as in sensi-
tivity analyses.
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OBJECTIVE: Access the Brazilian inﬂammatory bowel diseases
patients’ proﬁle METHODS: A retrospective database study was
performed in 23 IBD treatment centers in 14 Brazilian reference
cities. The centers collected data from the last 5 years about
personal data, disease important aspects (like race and smoking
habits), diagnosis and disease treatment. RESULTS: A total of
2529 medical records were analyzed. Crohnxs disease was the
most prevalent (49%) IBD. Sixty-ﬁve percent of the patients are
Caucasian and 9% are smokers. The median weight of the
patients are 62.5 kg and the median age 40.18% of the patients
came to the actual medical center with a previous IBD diagnostic
and 64% of this diagnosticated group came with a previous
treatment. CONCLUSION: This is the ﬁrst time that signiﬁcant
information about the Brazilian IBD patient proﬁle is evaluated.
Knowledge of the IBD could be a useful tool for supply policy
interventions. Combined with clinical data, this patient proﬁle
could contribute to the qualitative and quantitative evaluation of
disease management policy for this group pf illness.
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OBJECTIVE: To quantify preferences that ulcerative colitis (UC)
patients place on treatment attributes when making therapy
choices. METHODS: A telephonic survey of patients with
UC > 18 years old who requested information from the website
www.LivingWithUC.com from January to April 2006. Patients
were presented with nine factors that might impact a UC
patient’s decision-making process regarding whether to use a
biologic medication such as inﬂiximab. A discreet choice meth-
odology was employed using a complete block design, which
presented 9 factors being tested in 36 discreet pairs and patients
were asked to select the more important factor from each pair
presented. RESULTS: A total of 427 UC patients were contacted
to get 294 completed interviews. The median age was 50 years
and 204 (69.4%) were female. Of respondents currently on
medication, 71% indicated their symptoms were under control
and 75% of these respondents were experiencing 2 ﬂares per
year. One third (34%) of respondents classiﬁed their UC as being
moderate to severe. When asked about treatment options pre-
sented by their doctor, 42% had discussed surgery and 18% said
doctors indicated surgery was a cure for UC. Half (50%) recalled
their doctor presenting only one drug option, and of those pre-
sented with several options, 20% recall the physician emphasiz-
ing a particular drug. Respondents indicated healing the damage
of the intestinal lining (74%) and avoiding surgery (73%) were
important characteristics when deciding to use a product like
inﬂiximab to treat UC. Method of administration (23%) and cost
of co-pay (19%) were given least importance. CONCLUSION:
While doctors may focus on surgery as a cure for UC, patients in
this study state healing intestinal damage and avoiding surgery
would be their most important reasons to use a medication.
Doctors and patients may need to discuss a wider variety of
therapeutic options for treating UC before surgery is considered.
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OBJECTIVE: The Ontario Addiction Treatment Centres
(OATC) operates 26 clinics offering methadone maintenance
treatment (MMT) to clients with a dependence on opiates. Until
recently, MMT was a contraindication to antiviral therapy for
the treatment of Hepatitis C virus (HCV) infected patients. The
purpose of this study was 1) to describe a care model for treating
HCV infected MMT clients in a community-based setting, 2) to
describe clinical and demographic characteristics of these clients,
3) to assess rates of adherence to antiviral therapy, and 4) to
assess rates of sustained virological response (SVR). METHODS:
A review of patient medical records was employed. Clients con-
sidered for antiviral therapy at the OATC had achieved “func-
tional stability”, characterized by stable housing and a low
frequency of substance abuse, in addition to meeting clinical
criteria. Clients were followed by a hepatitis nurse, clinic physi-
cian or infectious disease specialist at the clinic where they
received methadone. Use of illicit substances was monitored
before, during and after antiviral therapy with regular urinalysis.
RESULTS: Between November 2002 and January 2006, 109
clients (75 with genotype 1/4 and 33 with genotype 2/3) received
at least one injection with pegylated interferon. The majority of
clients were single (60%), living in a permanent apartment or
house (94%), with a high frequency of self-reported psychiatric
disorders (68%). A large proportion had a criminal history
(71%) and many had been incarcerated (52%). Rates of adher-
ence to treatment of 57% and 70% were achieved for genotypes
1/4, and 2/3, respectively. Rates of SVR in an intention to treat
analysis were 51% for genotypes 1/4 and 64% for genotypes 2/3.
Six clients discontinued therapy due to on-going problems with
substance abuse. CONCLUSION: HCV antiviral therapy for
current or former substance abusers can be successful in the
context of specialized care for substance abuse.
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OBJECTIVE: To systematically review the effectiveness of pegy-
lated interferon (PEG), lamivudine (LAM), adefovir (ADF) and
entecavir (ENT) in treating CHB. METHODS: Pubmed, Embase,
Cochrane, and Econlit were searched for randomized controlled
trials assessing the efﬁcacy of the selected drugs for treating CHB
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